Caribou Biosciences (CRBU) Gains from Investment Securities (2020 - 2023)
Caribou Biosciences (CRBU) reported Gains from Investment Securities of $170000.0 for Q2 2023, down 79.62% year-over-year from $834150.0 in Q2 2022, and down 79.62% on a QoQ basis from $834150.0 in Q2 2022.
Caribou Biosciences (CRBU) has 4 years of Gains from Investment Securities data on file, last reported at $170000.0 in Q2 2023.
- Quarterly Gains from Investment Securities fell 79.62% year-over-year to $170000.0 in Q2 2023, while the trailing twelve-month figure through Sep 2024 was $170000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $2.1 million, changed N/A from the prior year.
- Gains from Investment Securities retreated to $170000.0 in Q2 2023 per CRBU's latest filing, from $834150.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $6.8 million in Q1 2022 and bottomed at $10000.0 in Q4 2020.
- The 4-year median for Gains from Investment Securities is $224849.5 (2020), against an average of $1.1 million.
- The widest annual swing landed in 2021, when Gains from Investment Securities jumped 980.0%; it then slumped 79.62% in 2023.
- Tracing CRBU's Gains from Investment Securities over 4 years: stood at $10000.0 in 2020, then jumped by 980.0% to $108000.0 in 2021, then surged by 672.36% to $834150.0 in 2022, then tumbled by 79.62% to $170000.0 in 2023.
- Per Business Quant, the three latest CRBU Gains from Investment Securities figures stand at $170000.0 (Q2 2023), $834150.0 (Q2 2022), and $6.8 million (Q1 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 170,000.00 |
| Jun 30, 2023 | 170,000.00 |
| Jun 30, 2022 | 834,150.00 |
| Jun 30, 2022 | 834,150.00 |
| Mar 31, 2022 | 6.84 Mn |
| Mar 31, 2022 | 6.84 Mn |
| Dec 31, 2021 | 108,000.00 |
| Dec 31, 2021 | 108,000.00 |
| Sep 30, 2021 | 138,420.00 |
| Sep 30, 2021 | 138,420.00 |
| Dec 31, 2020 | 10,000.00 |
| Dec 31, 2020 | 10,000.00 |
| Sep 30, 2020 | 379,761.00 |
| Sep 30, 2020 | 379,761.00 |
| Jun 30, 2020 | 279,699.00 |
| Jun 30, 2020 | 279,699.00 |